Diasorin S.p.A.
Italy · IT0003492391 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue +0.8% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 9.8% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 55% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
€1.2B
revenue
19%
operating margin
€156M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2021 | Dec 2022 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | €1.2B | €1.4B | €1.2B | €1.2B |
| Operating profit | €419M | €351M | €258M | €229M |
| Net profit to shareholders | €311M | €241M | €188M | €156M |
| Earnings per share | €5.44 | €4.16 | €3.35 | €2.92 |
| Dividend per share | n/a | €1.05 | n/a | €1.15 |
| Cash from operations | €401M | €389M | €359M | €343M |
| Capital spending | €68M | €53M | €52M | €62M |
| Cash | €403M | €242M | €344M | €166M |
| Total assets | €3.2B | €3.4B | €3.3B | €2.9B |
| Equity | €1.4B | €1.5B | €1.8B | €1.6B |
What they do
In the company's own words, from the annual report.
Il Gruppo Diasorin è specializzato nello sviluppo, nella produzione e commercializzazione di test di immunodiagnostica e di diagnostica molecolare.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.